CRCRISPR Therapeutics CRSP · NASDAQ
$54.26 +0.28% (+$0.15)
- Market cap
- $5.25B
- Enterprise value
- $5.74B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 391.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -21.1%
- Gross margin
- -1,534.4%
- Net margin
- -3,368.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.76
- Free float
- 99.5%
About the company
CRISPR Therapeutics AG is a Swiss biotechnology company specializing in the development of therapeutics based on the revolutionary CRISPR-Cas9 technology. This technology enables precise and efficient editing of genetic material, opening up new possibilities in treating genetic diseases and other conditions. CRISPR Therapeutics focuses its research on the treatment of various genetic disorders, including beta-thalassemia and muscular dystrophy. The company collaborates with renowned scientific institutions and experts to strengthen its research and develop new therapeutic approaches. CRISPR Therapeutics AG is an innovative player in the biotechnology industry and is committed to bringing revolutionary treatments to patients with genetic diseases. CRISPR Therapeutics AG (CRSP) shares represent an attractive investment opportunity for investors who follow the biotechnology sector and seek an innovative company engaged in treating genetic disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Samarth Kulkarni
Employees
393
Headquarters
Zug
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 100% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 1,052% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number